Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma

Hani M. Babiker, Irbaz B. Riaz, Syed R. Shah, Daniel D. von Hoff, Mitesh J Borad

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pancreatic cancer is an aggressive malignancy with poor survival and high mortality rate with 250 000 deaths per year worldwide. The unique pancreatic cancer microenvironment serves as a major obstacle in the effective treatment of this malignancy. The microenvironment consists not only of pancreatic ductal adenocarcinoma cells but also comprises cells of pancreatic cancer stellate, vascular, and immune origin combined with a dense extracellular matrix containing collagen. The aforementioned pathology leads to an increased intratumor pressure combined with an erratic vascular proliferation within the tumor causing hypoxia and decreased drug delivery. This has led both scientists and clinicians to develop and study drugs with unique mechanisms of action to target the pancreatic cancer microenvironment. Herein, we discuss the pancreatic cancer hypoxic microenvironment, development of hypoxia-activated prodrugs, and results of trials utilizing those drugs to target pancreatic cancer.

Original languageEnglish (US)
JournalAnti-Cancer Drugs
DOIs
StateAccepted/In press - Sep 28 2016

Fingerprint

Prodrugs
Pancreatic Neoplasms
Adenocarcinoma
Tumor Microenvironment
Blood Vessels
Pharmaceutical Preparations
Extracellular Matrix
Hypoxia
Neoplasms
Collagen
Pathology
Pressure
Mortality

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. / Babiker, Hani M.; Riaz, Irbaz B.; Shah, Syed R.; von Hoff, Daniel D.; Borad, Mitesh J.

In: Anti-Cancer Drugs, 28.09.2016.

Research output: Contribution to journalArticle

Babiker, Hani M. ; Riaz, Irbaz B. ; Shah, Syed R. ; von Hoff, Daniel D. ; Borad, Mitesh J. / Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. In: Anti-Cancer Drugs. 2016.
@article{3aede89186554274b3983fd6674a1746,
title = "Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma",
abstract = "Pancreatic cancer is an aggressive malignancy with poor survival and high mortality rate with 250 000 deaths per year worldwide. The unique pancreatic cancer microenvironment serves as a major obstacle in the effective treatment of this malignancy. The microenvironment consists not only of pancreatic ductal adenocarcinoma cells but also comprises cells of pancreatic cancer stellate, vascular, and immune origin combined with a dense extracellular matrix containing collagen. The aforementioned pathology leads to an increased intratumor pressure combined with an erratic vascular proliferation within the tumor causing hypoxia and decreased drug delivery. This has led both scientists and clinicians to develop and study drugs with unique mechanisms of action to target the pancreatic cancer microenvironment. Herein, we discuss the pancreatic cancer hypoxic microenvironment, development of hypoxia-activated prodrugs, and results of trials utilizing those drugs to target pancreatic cancer.",
author = "Babiker, {Hani M.} and Riaz, {Irbaz B.} and Shah, {Syed R.} and {von Hoff}, {Daniel D.} and Borad, {Mitesh J}",
year = "2016",
month = "9",
day = "28",
doi = "10.1097/CAD.0000000000000437",
language = "English (US)",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma

AU - Babiker, Hani M.

AU - Riaz, Irbaz B.

AU - Shah, Syed R.

AU - von Hoff, Daniel D.

AU - Borad, Mitesh J

PY - 2016/9/28

Y1 - 2016/9/28

N2 - Pancreatic cancer is an aggressive malignancy with poor survival and high mortality rate with 250 000 deaths per year worldwide. The unique pancreatic cancer microenvironment serves as a major obstacle in the effective treatment of this malignancy. The microenvironment consists not only of pancreatic ductal adenocarcinoma cells but also comprises cells of pancreatic cancer stellate, vascular, and immune origin combined with a dense extracellular matrix containing collagen. The aforementioned pathology leads to an increased intratumor pressure combined with an erratic vascular proliferation within the tumor causing hypoxia and decreased drug delivery. This has led both scientists and clinicians to develop and study drugs with unique mechanisms of action to target the pancreatic cancer microenvironment. Herein, we discuss the pancreatic cancer hypoxic microenvironment, development of hypoxia-activated prodrugs, and results of trials utilizing those drugs to target pancreatic cancer.

AB - Pancreatic cancer is an aggressive malignancy with poor survival and high mortality rate with 250 000 deaths per year worldwide. The unique pancreatic cancer microenvironment serves as a major obstacle in the effective treatment of this malignancy. The microenvironment consists not only of pancreatic ductal adenocarcinoma cells but also comprises cells of pancreatic cancer stellate, vascular, and immune origin combined with a dense extracellular matrix containing collagen. The aforementioned pathology leads to an increased intratumor pressure combined with an erratic vascular proliferation within the tumor causing hypoxia and decreased drug delivery. This has led both scientists and clinicians to develop and study drugs with unique mechanisms of action to target the pancreatic cancer microenvironment. Herein, we discuss the pancreatic cancer hypoxic microenvironment, development of hypoxia-activated prodrugs, and results of trials utilizing those drugs to target pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84989257454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989257454&partnerID=8YFLogxK

U2 - 10.1097/CAD.0000000000000437

DO - 10.1097/CAD.0000000000000437

M3 - Article

C2 - 27685167

AN - SCOPUS:84989257454

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

ER -